Telehealth Tirzepatide

Tirzepatide References: Full Citation List

All Tirzepatide citations used on this site

Every quantitative claim on this site cites one of the following peer-reviewed publications. DOIs and PubMed links are provided for each.

  1. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018. ↗
  2. Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. ↗
  3. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. ↗
  4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. ↗
  5. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. ↗
  6. Qazi S, et al. Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Healthcare (Basel). 2026. ↗
  7. Farzam K, Patel P. Tirzepatide (StatPearls). StatPearls [Internet], NCBI Bookshelf. 2024. ↗
  8. Pan XH, et al. Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obesity (Silver Spring). 2024. ↗
  9. Kadowaki T, et al. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Diabetes Endocrinol. 2025. ↗
  10. Gudzune KA, et al. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study. Diabetes Obes Metab. 2025. ↗
  11. Horn DB, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025. ↗
  12. Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024. ↗
  13. Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025. ↗
  14. Loomba R, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024. ↗
  15. Linetzky B, et al. Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide. Ann Intern Med. 2025. ↗
  16. Galindo RJ, et al. Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials. JAMA Netw Open. 2026. ↗
  17. U.S. Food and Drug Administration. FDA approves new medication for chronic weight management. FDA News & Events. 2023. ↗
  18. Berg S, et al. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis. Obes Rev. 2025. ↗
  19. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024. ↗
  20. Horn DB, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal. JAMA Intern Med. 2026. ↗
  21. Safwan M, et al. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obesity without diabetes: a meta-analysis. Ann Saudi Med. 2025. ↗
  22. Mishra R, et al. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review. Cureus. 2023. ↗
  23. Shen P, et al. Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance study. PLoS One. 2026. ↗
  24. Kunutsor SK, et al. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Review. Drugs. 2026. ↗
  25. Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023. ↗
  26. U.S. Food and Drug Administration. Tirzepatide injection prescribing information (FDA label, type 2 diabetes indication). FDA Drugs@FDA. 2022. ↗
  27. Farzam K, Patel P. Tirzepatide (StatPearls) — regulatory and safety summary. StatPearls [Internet], NCBI Bookshelf. 2024. ↗
  28. Zhang Z, et al. Tirzepatide safety in type 2 diabetes: a disproportionality analysis of the FDA Adverse Event Reporting System. Endocr Connect. 2025. ↗
  29. Kunutsor SK, et al. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists (thyroid/class warning context). Drugs. 2026. ↗
  30. Nassar M, et al. Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide. Diabetes Metab Syndr. 2024. ↗
  31. Gong J, et al. Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide. J Diabetes Investig. 2025. ↗
  32. Galli M, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Network Meta-Analysis. J Am Coll Cardiol. 2025. ↗
  33. Rasouli N, et al. Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Pooled SURPASS Analysis. Diabetes Ther. 2025. ↗
  34. Jalleh RJ, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists — Perioperative Considerations. J Clin Endocrinol Metab. 2024. ↗
  35. Urva S, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020. ↗
  36. Look M, et al. Body composition changes during weight reduction with tirzepatide in type 2 diabetes (DXA substudy). Diabetes Obes Metab. 2025. ↗
  37. Batsis JA, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review. Ann Intern Med. 2026. ↗
  38. Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024. ↗
  39. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. Cureus. 2025. ↗
  40. Campbell JE, et al. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss — chemistry, physiology, and clinical applications. Cell Metab. 2023. ↗
  41. Yin Y, et al. Tirzepatide monotherapy in Chinese patients with early type 2 diabetes (SURPASS-CN-MONO). Med. 2026. ↗